

Alternative Reporting Standard: Disclosure Guidelines for the Pink[®] Market

Blue Star Opportunities Corp.

A Nevada Corporation

50 West Liberty Street, Suite 880, Reno, Nevada 89501, USA

(438)501-6500

info@bstoai.com

Quarterly Report

For the period ending September 30, 2024 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

122,602,694 of September 30, 2024 (Current Reporting Period Date or More Recent Date)

122,602,694 as of December 31, 2023 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Present Name: Blue Star Opportunities Corp.

f/k/a Green Zap Inc. until July 14, 2008.

f/k/a NPW Development Inc. until October 31, 2005.

f/k/a NPower Digital Media Inc. until July 8, 2005.

f/k/a/ ERICA until June 14, 2005.

f/k/a Window Interior Marketing Company from September 9, 1986, until September 8, 1992.

Originally incorporated in the State of Nevada on September 9, 1986, under the name Window Interior Marketing Company.

The Corporation's name was changed to Blue Star Opportunities Corp. on July 14, 2008.

Current State and Date of Incorporation or Registration:

Originally incorporated in the State of Nevada on September 9, 1986

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

50 West Liberty Street, suite 880
Reno, Nevada, 89501
USA
info@bstoai.com

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

4999 Rue Louis-B. Mayer, Laval, QC H7P 0G1

Phone: (450) 978-3403

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes provide additional details below:

2) Security Information

Transfer Agent

Name: Liberty Stock Transfer

Phone: +1-732-372-0707

Email: info@libtystocktransfer.com

Address: 788 Shrewsbury Ave., Suite 2163, Tinton Falls, NJ 07724, USA

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>BSTO</u>
Exact title and class of securities outstanding:	<u>Common Shares</u>
CUSIP:	<u>096060 108</u>
Par or stated value:	<u>\$0.0001.</u>
Total shares authorized:	<u>350,000,000</u> as of date: September 30,2024
Total shares outstanding:	<u>122,602,694</u> as of date: September 30,2024
Total number of shareholders of record:	<u>245</u> as of date: September 30,2024

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

N/A

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security: Preferred Series A
CUSIP (if applicable): _____
Par or stated value: \$10.
Total shares authorized: 1000 as of date: September 30,2024
Total shares outstanding (if applicable): 0 as of date: September 30,2024
Total number of shareholders of record 0 as of date: September 30,2024

Exact title and class of the security: Preferred Series B
CUSIP (if applicable): _____
Par or stated value: \$0.0001.
Total shares authorized: 25,000 as of date: September 30,2024
Total shares outstanding (if applicable): 0 as of date: September 30,2024
Total number of shareholders of record (if applicable): 0 as of date: September 30,2024

Exact title and class of the security: Preferred Series C
CUSIP (if applicable): _____
Par or stated value: \$0.0001
Total shares authorized: 2000 as of date: September 30,2024
Total shares outstanding (if applicable): 0 as of date: September 30,2024
Total number of shareholders of record (if applicable): 0 as of date: September 30,2024

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

N/A

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. **For common equity, describe any dividend, voting and preemption rights.**

One vote per share, no dividend, no preemptive rights.

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

Preferred A. As a class holds a supermajority vote of 51%. Have no conversion rights.

Preferred B. Non-Voting. Carries a dividend at the rate per annum of five percent (5%) of the Stated Value per share shall accrue on each outstanding share from and after the date of the original issuance of such shares. (Subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock) .The Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative and non-compounding; provided, however, that such Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Preferred Accruing Dividends. The Board of Directors and the Corporation can elect to pay dividends owed in cash or in common shares. No cash dividends shall be paid on the Common Stock unless the Preferred Accruing Dividends are paid. Except for stock dividends or distributions for which adjustments are to be made pursuant to Section 7, Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.

Preferred C. Non-Voting. Convertible into common stock at the same conditions as Preferred B shares described above.

3. **Describe any other material rights of common or preferred stockholders.**

N/A

4. **Describe any material modifications to the rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

N/A

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: X Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> : Date _____ Common: _____ Preferred: _____			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
_____	_____	_____	_____	_____	_____	_____	_____	_____	
_____	_____	_____	_____	_____	_____	_____	_____	_____	
_____	_____	_____	_____	_____	_____	_____	_____	_____	
Shares Outstanding on Date of This Report: <u>Ending Balance</u> : Date _____ Common: _____ Preferred: _____									

Example: A company with a fiscal year end of December 31st, 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)

_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

4) Issuer’s Business, Products and Services

The purpose of this section is to provide a clear description of the issuer’s current operations. Ensure that these descriptions are updated on the Company’s Profile on www.OTCMarkets.com.

- A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”)

Clinical AI Development

Earlier in the year, the company brought to a successful conclusion negotiation that had been pursued towards the acquisition of a new line of business in the field of AI clinical analytics intelligence. The company had been presented with the opportunity to acquire a personal medical advisory business that can be deployed online to serve people with medical or sports related conditions who wish to monitor the quality of clinical care they receive. The intelligence and clinical workflow in the system had been used over many years in tertiary care University hospital centers but now, due to ongoing progress in generative artificial intelligence, the system was able to be adapted for online use by consumers who wish to monitor their own clinical care.

The Company was able to rely on the clinical expertise of its collaborator, Stella Papadoukakis, as well as its software engineers in assessing this opportunity as well as other potential acquisitions in clinical AI. The Company’s AI intelligent Clinical management system includes applications designed to help individuals protect themselves from prescription medication errors, one of the leading causes of morbidity and mortality in both North America and Western Europe. This acquisition marks a decisive pivot of the company towards new business in the field of AI clinical analytics intelligence.

While developing its Clinical AI business, the Company has continued to increase its revenues in Q3 2024.

- B. List any subsidiaries, parent company, or affiliated companies.

Laurel Leaf LLC of Colorado Springs, CO

- C. Describe the issuers’ principal products or services.

A generative AI intelligent clinical system for the detection of medication risk is the main product that will drive the company’s growth. Included is a consumer medical advisory service deployed online to serve people with medical or sports related conditions who wish to monitor the quality of clinical care they receive. The intelligence and clinical analytics in the system come from early AI systems

successfully tested over many years in tertiary care hospitals and is now in the process of being made available online for consumers who wish to monitor their own clinical care, especially monitoring medications risk and dangers. The system is likely to be critically important for consumers who are chronic users of prescription drugs, as well as others who use over the counter medicine, which medical literature demonstrates are not without associated risks.

In the management of medical errors but especially wrongful medication use, the availability of our new AI protocols is a game changer for individuals who wish to manage such clinical risk factors. In surveying the extent of medical errors, especially medication errors (Adverse Drug Events or ADE), among other studies of the subject, John Hopkins clinical studies suggest that medical errors could be the third cause of death in US surpassed only by heart disease and cancer. This confirms that not much progress is being made by the health system towards the prevention of these errors since The National Institute of Health advocated the use of technology to prevent adverse drug events in its 1999 report, *To Err is Human*. Research literature shows Adverse Drug Events, or ADEs, continue to be a serious concern in healthcare today. These events occur when patients experience harmful or unintended reactions to medications.

ADEs can range from mild side effects like nausea or dizziness to severe complications such as organ damage or allergic reactions. Unfortunately, healthcare providers are not vigilant in monitoring patients for signs of ADEs because of the lack of proper information management. The Company's Diomedes AI system goes a long way towards preventing these medication risks. Its capacity for prevention had been tested in major tertiary care hospitals including McGill University affiliates, where it reduced medication errors by 80% as well as reducing inpatient mortality by 50%. It can now be made available to individuals online, a development made economically feasible by using the recent advances in artificial intelligence.

Our Diomedes AI will allow individuals to monitor their own medication safety and help make up for the lack of prevention vigilance from HMOs and other provider organizations. Our deep bench of expertise in AI clinical analytics intelligence gives the Company a certain advantage in making further acquisitions in personal health space.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

We do not own any real estate property or any long-term lease.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Names of All Officers, Directors, and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Joseph Hozer</u>	<u>Chair</u>	<u>Montreal, Quebec</u>	<u>49 M</u>	<u>Common</u>	<u>40%</u>	<u>_____</u>
<u>Laurel Harris</u>	<u>President</u>	<u>Colorado Springs, CO</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>
<u>Laurel Leaf LLC</u>	<u>Owner</u>	<u>Colorado Springs, CO</u>	<u>50 M</u>	<u>Common</u>	<u>40.8 %</u>	<u>Laurel Harris</u>
<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>
<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>	<u>_____</u>

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

NO

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

NO

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

NO

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

NO

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NO

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

NO

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Morgan E. Petitti, Esq.
Address 1: 118 W. Streetsboro Road, # 317, Hudson, Ohio 44236, USA
Address 2: _____
Phone: 330 697 8548
Email: PetittiLaw@gmail.com

Accountant or Auditor

Name: Nicolas Kanellopoulos, CMA
Firm: TriLogic - Accounting, Organizational, Management solutions
Address 1: Chabanel Street West, suite 1114, Montréal, QC H2N 2C4
Address 2: _____
Phone: (514) 995 7017

Email: nicolas@trilogic-fn.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

Twitter: _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) **that assisted, advised, prepared, or provided information with respect to this disclosure statement.** This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Michel Dab
Firm: 11324136 Canada Corp
Nature of Services: Management Consultant
Address 1: 50 High Park Avenue, Suite 16009,
Address 2: Toronto, ON M6P 2R9
Phone: (647)581-9610
Email: micheldab76@gmail.com

9) Financial Statements

A. This Disclosure Statement was prepared by (name of individual):

Name: Michel Dab
Title: Consultant
Relationship to Issuer: None

B. The following financial statements were prepared in accordance with:

- IFRS
- U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Michel Dab

Title: Consultant

Relationship to Issuer: None.

Describe the qualifications of the person or persons who prepared the financial statements:

Michel Dab has served for over 12 years as a financial manager for US public Companies, preparing financial statements and supervising the relationship with auditors. These Statements were prepared with assistance from Nicolas Kanellopoulos, CMA.

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- Audit letter, if audited.
- Balance Sheet.
- Statement of Income.
- Statement of Cash Flows.
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

FINANCIAL STATEMENTS		
Blue Star Opportunities Corp.		
BALANCE SHEET		
Q3 2024		
	30-Sep-24	30-Sept.-2023
	Q3	Q3
	\$	\$
ASSETS		
CURRENT		
Cash	-	54,525
Receivables	206,777	414,657
Other current assets	793,667	468,925
	1,000,444	938,107
FIXED ASSETS	869,262	584,309
INTANGIBLE ASSETS	5,733,923	5,733,923
TOTAL	7,603,629	7,256,339
LIABILITIES		
CURRENT		
Accounts payable	611,788	576,651
Short term loans		115,000
Other current liabilities	441,184	341,177
	1,052,972	917,828
DEFERRED REVENUE	-	-
SHAREHOLDERS' EQUITY		
Capital Surplus	-	-
Stockholder equity - Issued 122,602,694 Shares	4,516,383	4,516,383
Retained earnings (Deficit)	2,034,274	2,090,074
	6,550,657	6,606,457
	7,603,629	7,524,285

Blue Star Opportunities Corp.		
INCOME AND EXPENSES		
	30-Sep-24	30-Sept.-2023
	Q3	Q3
	\$	\$
REVENUE	2,900,889	2,813,137
OPERATING EXPENSES		
Cost of revenue	1,707,840	1,555,614
Research & Development	-	-
Selling, general and administrative	799,291	768,695
Other	286,257	220,882
	2,793,388	2,545,191
NET INCOME (LOSS) BEFORE INTEREST AND OTHER	107,501	267,946
INTEREST AND OTHER		
Financial expenses	-	-
Other expenses (income)	-	-
NET INCOME (LOSS) FOR THE QUARTER	107,501	267,946
PER SHARE	0.0009	0.0022
Blue Star Opportunities Corp.		
RETAINED EARNINGS (DEFICIT)		
	30-Sep-24	30-Sept.-2023
	Q3	Q3
	\$	\$
<i>Retained Earnings, at beginning</i>	1,926,773	1,822,128
<i>Net income (loss)</i>	107,501	267,946
<i>Balance, at end</i>	2,034,274	2,090,074

Blue Star Opportunities Corp.		
CHANGES IN SHAREHOLDERS EQUITY	30-Sep-24	30-Sept.-2023
	Q3	Q3
	\$	\$
Common Shares, at beginning	122,602,614	122,602,614
Changes	-	-
Common Shares, at end	122,602,614	122,602,614
Common Stock, at beginning	4,516,383	4,516,383
Changes		-
Common Stock, at end	4,516,383	4,516,383
Additional Paid-In Capital, at beginning	-	
Changes	-	
Additional Paid-In Capital, at end	-	
Accumulated Earnings	1,926,773	1,926,773
Changes	107,501	267,946
Accumulated Earnings	2,034,274	2,194,719
Total Shareholders' Equity, at beginning	6,443,156	6,443,156
Changes	107,501	267,946
Total Shareholders' Equity, at end	6,550,657	6,711,102

Blue Star Opportunities Corp.		
Statement of Cash Flows		
Q3 2024		
	30-Sep-24	30-Sept.-2023
	Q3	Q3
	\$	\$
Operating Activities		
Net income (Loss)	107,501	267,946
Depreciation	-	
Accounts Receivables	74,200	(180,159)
Other assets	(89,939)	(68,355)
Prepaid expenses and deposits	-	
(Decrease) Increase in accounts payable and accrued liabilities	268,519	321,795
Cash (used in) operating activities	360,281	341,227
Financing Activities		
Reduction in Capital Surplus	-	
Changes in capital stock	-	-
Cash provided by financing activities	-	-
Investing activities		
Reduction to fixed assets	(360,281)	(305,201)
Additions to intangible assets	-	
Cash flows provided by (used in) investing activities	(360,281)	(305,201)
(Decrease) Increase Cash and cash equivalents	-	36,026
Beginning of period	-	18,499
End of period	-	54,525

1. Growth Company

The Company was Originally incorporated under the laws of the State of Nevada on September 9, 1986, as Window Interior Marketing Company. The Company changed its name to Blue Star Opportunities Corp. on July 14, 2008. The Company's first shareholder is Mr. Joseph Hozer of Montreal, Canada, who also serves as Company Chairman of Blue Star Opportunities Corp. has been a highly creative designer and creator of high end environmentally friendly flooring materials. Its Duro-Design brand is well established in the North American cork flooring market. The Company has many institutional installations in Universities, Museums, high tech companies, hotels and churches.

The company is still in the process of diversifying from its activities through acquisitions. During the Quarter, the Company negotiated to acquire the rights to an advanced AI medical error prevention system with Montreal based Sygenics Inc. The plan is to make the system, Diomedes MedGuard, available online so individuals can monitor for themselves the risk factors associated with their own use of medication and procedures. It is estimated that there is a substantial safety benefit in using this system considering that drug errors alone are the third cause of death in the US where the health system is failing in spite of repeated warnings from the National Institutes of Health (NIH). The Company is planning to make the Diomedes MedGuard System available online for personal use by individuals.

In the course of the quarter, the company entered into a series of Strategic Agreements with Nutrific, Inc of Cheyenne, Wyoming 82001, also with offices in Aliso Viejo, California, to acquire from Nutrific the worldwide distribution rights for their next generation of science-based natural healthcare products. Following this non-dilutive opportunity, we decided to additionally add potent natural extracts to augment the human immune system, which we see as having a similar focus as our preventative systems in the medical arena; the core concept of new and more powerful natural extracts is undervalued in the company's opinion and needs to take more importance in the daily lives of those people who want to optimize their immune systems, thereby also enabling synthetic drugs to potentially work more effectively.

2. Summary of Significant Accounting Principles

a) Basis of Presentation and Fiscal Year

These are the Quarterly financial statements prepared for Q3 2024 that closed on September 30, 2024. prepared in accordance with GAAP.

b) Use of Estimates

The Company regularly evaluates estimates and assumptions related to useful life and recoverability of long-lived assets, allowances for doubtful accounts, sales returns and allowances, inventory reserves, stock-based compensation expense, warranty liabilities and deferred income tax asset valuations. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources

c) Cash and Cash Equivalents, the Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

3. Summary of Significant Accounting Policies (continued)

a) Allowance for Doubtful Accounts

The Company evaluates the collectability of accounts receivable based on a combination of factors. In cases where the Company is aware of circumstances that may impair a specific customer's ability to meet its financial obligations subsequent to the original sale, the Company will record an allowance against amounts due, and thereby reduce the net recognized receivable to the amount the Company reasonably believes will be collected. The allowance for doubtful accounts as of September 30, 2024, was negligible.

b) Property and Equipment- fixed assets

Property and equipment are stated at cost, less accumulated amortization, and consists of office furniture and equipment, leasehold improvements and assets under capital lease. Amortization of office furniture is computed using the straight-line method over five years. Amortization of computer hardware and software is computed using the straight-line method over three years. Amortization of leasehold improvements is computed using the straight-line method over five years. Amortization of assets under capital lease is computed using the straight-line method over the term of the lease.

c) Long-Lived Assets

In accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. The rise in assets is due in part to the acquisition of new product and to an increased value of our commercial agreements.

d) Development Costs

Costs related to the enhancement of internally developed or purchased products are charged to operations. The Company has not capitalized any product development costs during the period.

e) Basic and Diluted Net Income (Loss) Per Share

The Company computes net income (loss) per share in accordance with SFAS No. 128, "Earnings per Share" which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all diluted potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible preferred stock, using the if-converted method.

f) Financial Instruments

The carrying value of cash, accounts receivable, advances to related parties, other assets, accounts payable, accrued liabilities, advances from related parties and capital lease obligation approximate fair value due to the relatively short maturity of these instruments. Financial instruments which potentially subject the Company to a concentration of credit risk consist primarily of cash and accounts receivable. The Company deposits cash with a high- quality financial institution.

g) Inventory

The value of inventories as of September 30,2024, was \$756,876. Inventory is stated at a lower cost or net realizable value.

h) Revenue Recognition

Staff Accounting Bulletin No. 104 "Revenue Recognition", revenue will only be recognized when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured. The Company's revenue contracts are accounted for in conformity with Accounting Research Bulletin No. 45 "Long-Term Construction-Type Contracts" ("ARB 45"), using the relevant guidance in SOP 81-1 "Accounting for Performance of Construction-Type and Certain Production-Type Contracts", unless specified criteria for separate accounting for any service element are met. The Company uses the completed contract method to recognize revenues from finished product sales.

i) Comprehensive Loss

SFAS No. 130, "Reporting Comprehensive Income," establishes standards for the reporting and display of comprehensive loss and its components in financial statements.

j) Reclassifications

No reclassifications have been made to the prior period's financial statements.

k) Advertising Costs

Advertising costs are charged to operations as incurred.

l) Stock-based Compensation.

There was no stock-based compensation for the period. Accordingly, there was no effect on the Company's reported gain from operations, cash flows or earnings per share as a result of adopting SFAS No 123R.

m) Recently Issued Accounting Pronouncements

n) Provision Against Future Cost Overrun

The Company has made no provision against potential future cost overruns related to the implementation of its Software Solutions, and the provision of services to its clients

4. Advances to Related Parties

None.

5. Advances from Related Parties

None.

6. Preferred Stock

For the quarter ending September 30,2024 the Company issued no Preferred Stock.

7. Common Stock

For the quarter ending September 30,2024, the Company issued no Common shares.

8. Stock Options

For the quarter ended September 30,2024 September 30,2024, the Company issued no options.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Laurel Harris do certify that:

1. I have reviewed this Disclosure Statement for Blue Star Opportunities Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 22, 2024

"/s/ (Laurel Harris)"

Principal Financial Officer:

I, Joseph Hozer do certify that:

1. I have reviewed this Disclosure Statement for Blue Star Opportunities Corp.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 22,2024

"/s/ (Joseph Hozer)"